Skip to main
TLX

TLX Stock Forecast & Price Target

TLX Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Telix Pharmaceuticals has demonstrated strong financial growth, reporting total revenue of $230 million for the first quarter of 2026, reflecting an 11% quarter-over-quarter increase and a 23% year-over-year growth, largely driven by its Precision Medicine unit. The company has experienced a 16% quarter-over-quarter growth in precision medicine revenue, attributed to increased uptake of Gozellix and sustained demand for Illuccix, which positions Telix favorably in the imaging and treatment landscape for prostate cancer. Additionally, potential regulatory milestones, including reimbursement securement in European markets and anticipated marketing approval in China, could further enhance growth prospects and solidify Telix's competitive advantage in the radiopharmaceutical sector.

Bears say

Telix Pharmaceuticals faces several critical risks that contribute to a negative outlook on its stock, primarily stemming from potential negative clinical results with its lead therapeutic asset, TLX591, and delays in advancing pipeline candidates into crucial registrational programs. Additionally, there are concerns regarding the company's ability to secure timely regulatory approvals, alongside competitive pressures from alternative radiopharmaceuticals and modalities that may hinder its market position. The presence of long-term dilution risk further compounds these issues, emphasizing uncertainties related to future earnings and overall financial stability.

TLX has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Telix Pharmaceuticals Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Telix Pharmaceuticals Ltd (TLX) Forecast

Analysts have given TLX a Strong Buy based on their latest research and market trends.

According to 4 analysts, TLX has a Strong Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Telix Pharmaceuticals Ltd (TLX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.